Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival-Reference-Cited by-同舟云学术

Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival

Published:2003-03-01 Issue:3 Volume:18 Page:482-492
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Croucher Peter I,De Raeve Hendrik,Perry Mark J,Hijzen Anja,Shipman Claire M,Lippitt Jennifer,Green Jonathan,Van Marck Eric,Van Camp Ben,Vanderkerken Karin

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference51 articles.

1. Quantitative histology of myeloma-induced bone changes;Valentin-Opran;Br J Haematol,1982

2. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma;Bataille;J Clin Invest,1991

3. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indicies of bone resorption;Taube;Eur J Haematol,1992

4. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma;Roux;Bone,1994

5. Production of interleukin 1 by bone marrow myeloma cells;Cozzolino;Blood,1989

Cited by 239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone niches in the regulation of tumour cell dormancy;Journal of Bone Oncology;2024-08

2. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease;Nature Communications;2024-03-19

3. Protective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma;Biomedicines;2024-02-24

4. Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients;Cancer Innovation;2024-02

5. Anti-Angiogenic Activity of Drugs in Multiple Myeloma;Cancers;2023-03-27